Cellular Target Engagement and Dissociation Kinetics of Class I-Selective Histone Deacetylase (HDAC) Inhibitors.

Irina Honin, Zora Novakova, Felix Feller, Simon Schneider, Linda Schäker-Hübner, Cyril Barinka, Finn K. Hansen

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Irina HoninDepartment of Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany.

Zora NovakovaInstitute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 252 50 Vestec, Czech Republic.ORCID 0000-0001-9804-6346

Felix FellerDepartment of Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany.

Simon SchneiderBonn Technology Campus, Core Facility 'Gene-Editing', Medical Faculty, University of Bonn, 53127 Bonn, Germany.ORCID 0000-0001-9894-5608

Linda Schäker-HübnerDepartment of Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany.ORCID 0000-0001-7734-124X

Cyril BarinkaInstitute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 252 50 Vestec, Czech Republic.ORCID 0000-0003-2751-3060

Finn K. HansenDepartment of Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany.ORCID 0000-0001-9765-5975

Funding

CAS 86652036German Research Foundation 494832089MEYS CR LUAUS23247

6 · The paper itself

Abstract

Histone deacetylases (HDACs) 1-3 are key regulators of gene expression and represent important therapeutic targets in cancer, neurodegenerative, and immune disorders. Many potent class I HDAC inhibitors display slow- and tight-binding kinetics, which profoundly influence their efficacy and pharmacodynamics. In particular, their dissociation rate (

Indexed as

Histone Deacetylase InhibitorsHistone DeacetylasesHumansHydroxamic AcidsKineticsProtein BindingVorinostatHistone Deacetylase InhibitorsHistone DeacetylasesHydroxamic AcidsVorinostatdissociation behaviorepigeneticsHDAC inhibitor (HDACi)histone deacetylase (HDAC)NanoBiTNanoBRETresidence time

Identifiers

PMID41977225

DOI10.3390/ijms27073036

PMCPMC13073407

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.